Last updated: 14 November 2026
This page explains what PeptGuru will and will not use as a source, and why. It applies to every factual and regulatory statement on the site.
Sources we use
Scientific studies. Original peer-reviewed research: laboratory (in-vitro), animal or preclinical, human observational, human clinical trial, or randomised controlled trial (RCT) research, published in a recognised, indexed journal with named authors and a stated methodology. We record the journal article itself (with its DOI and, where available, its PMID) as the source, not a discovery index such as PubMed, which points to articles rather than being a source in its own right.
Preprints (research shared before formal peer review, for example on medRxiv or bioRxiv) are used only where clearly labelled as preprints, and are never treated as more than the lowest strength of evidence on this site. Once a preprint is published in a peer-reviewed journal, we cite the published version.
Systematic reviews and meta-analyses. Cochrane Library reviews and other systematic reviews or meta-analyses published in peer-reviewed journals following recognised reporting standards (PRISMA). These pool and weigh multiple studies and are generally the strongest single type of source for a research finding.
Academic publications. Peer-reviewed narrative reviews, established academic textbooks and peer-reviewed conference material. These are useful for background and classification, but we avoid relying on them alone for a specific efficacy or safety claim where a direct study or systematic review is available.
Regulatory documents. Official material from the MHRA (the UK's medicines regulator) and UK medicines legislation, and, for context only, FDA or EMA material. UK status always comes from the MHRA or UK legislation, never inferred from another country's regulatory position.
Government sources. Official UK government publications relevant to a substance's legal status, such as gov.uk guidance, Home Office material where controlled-substance status is relevant, and legislation.gov.uk statute text.
Official clinical information. NHS.uk clinical pages, NICE guidance, and clinical trial registry entries (such as ClinicalTrials.gov), used to record that a trial exists and how it was designed. A registered trial is not treated as evidence of a result until its results are published.
Every source has its own source page showing its design, limitations and retraction status, and the findings that cite it.
Sources we do not use
We deliberately exclude several categories of material that circulate widely online on this topic, because they do not meet a basic standard of verifiability, editorial oversight or independence:
- Forums and community discussion (such as Reddit or bodybuilding and biohacking forums): anecdotal and unverifiable.
- Social media posts, whatever the poster's claimed credentials, unless the post simply points to a genuine underlying source, in which case we cite that source directly.
- Vendor and seller marketing content. This is the most important exclusion for this site. Sellers of peptides labelled for research routinely publish informational-looking content about legality and research findings on their own commercial sites. We do not use it, however authoritative it reads, because the publisher has a direct commercial interest in the answer.
- Uncited secondary blogs and generic health-guide content that state a claim without pointing to a traceable primary source. Where such content cites a real study, we go to the study itself.
- Wikipedia: useful for general background only, never cited directly.
- Press releases describing a study before its publication. We wait for, and cite, the published paper.
- Sponsored or advertorial content, however professionally produced.
Regulatory and government sources are assessed differently
A scientific study and an MHRA notice answer different kinds of question, so we do not apply the same evidence-strength scale to both. Research sources are assessed for how strong the evidence is that something happens or works (see How evidence strength is decided). Regulatory and government sources are checked for:
- Authority: is this the body with jurisdiction over the claim, such as the MHRA for UK medicinal-product status, rather than a secondary summary of what a regulator has said?
- Specificity: does the source name this exact substance, or is a general statement being applied to it by inference? Where we apply a general regulatory statement to a specific peptide by inference, we say so rather than presenting it as if the peptide were named.
- Currency: regulatory status can change, so we record and display the date each regulatory source was last checked. Our aim is to re-check at least once a year, and sooner when a relevant MHRA update comes to our attention.
A note on our own process
This policy reflects long-established conventions in evidence assessment, including the standard hierarchy of human, animal and laboratory evidence; peer review and journal indexing as quality signals; and the MHRA's role as the UK's medicines regulator. It is not a claim that the policy has been independently certified by an outside body. Where genuinely qualified scientific, medical or regulatory reviewers are engaged in future, their review of specific content will be credited on the pages they reviewed. See the Medical Disclaimer for the full statement on authorship and review.
